HCMSG The Hepatitis C Mentor & Support Group, Inc.
Search
  • Home
  • About Us
    • Our Mission
    • Board of Directors
  • Resources
    • Hep C Facts & Stats
    • Patient Assistance Programs
    • Research and Publications
    • Reading
    • Links
  • Programs/Training
    • The Hepatitis C Education and Support Group Assistance Program
    • The Circle Model >
      • THE CIRCLE Registration
    • Healthcare Provider Training
  • Newsletter
  • Blog
  • Support Us
  • Contact Us

Daktari Achieves Milestone in Its Merck HCV Collaboration

2/5/2017

0 Comments

 
January 25, 2017 08:00 ET | Source: Daktari DiagnosticsCAMBRIDGE, Mass., Jan. 25, 2017 (GLOBE NEWSWIRE) -- Daktari Diagnostics, a company focused on making “Anywhere. Care.™” a reality with its portable and ultrasensitive immunoassay-based CarePlatform™, today announced that it has reached a milestone in its global collaboration with Merck, known as MSD outside the United States and Canada, for the development of Daktari’s rapid point-of-care (POC) hepatitis C virus (HCV) core antigen confirmatory test system.
Daktari has successfully completed the design of the cartridge prototype suitable for commercial production, triggering a milestone payment of an undisclosed sum from Merck.
Daktari’s developmental HCV POC system is designed to provide quantitative determination of HCV viral load as a means to confirm diagnosis of an active HCV infection from samples of whole blood. It is based on a high-sensitivity measurement of the HCV core antigen and allows for a single-test approach, reducing the need for patients to undergo multiple diagnostic tests, especially in low access settings. The POC system consists of an automated instrument with an integrated reagent cartridge subsystem.
Of the approximately 130-150 million people around the world living with chronic HCV, up to 80 percent are asymptomatic after initial infection, underscoring the need for a simple, quick, cost-effective confirmatory test to aid in rapid diagnosis and help prevent further disease transmission. In 2016, the World Health Assembly, as the decision-making body of the World Health Organization, adopted the first-ever global strategy on hepatitis focused on eradicating HCV as a public health problem by reducing new infections by 90 percent by 20301. In the U.S., the Centers for Disease Control and Prevention (CDC) recommends HCV screening for all people born in the years 1945-19652
https://globenewswire.com/news-release/2017/01/25/910734/0/en/Daktari-Achieves-Milestone-in-Its-Merck-HCV-Collaboration.html
About Daktari Diagnostics
Daktari Diagnostics, a privately held company based in Cambridge, Mass., is focused on developing ultrasensitive, point-of-care diagnostics that enable timely testing and access to healthcare so that patients around the world can be linked to appropriate care. Daktari’s immunoassay CarePlatform™ encompasses a proprietary diagnostic detection technology, a highly portable device, automated sample preparation with whole blood in a single-use disposable cartridge, and a wireless, cloud-based connectivity platform to allow seamless data management for enhanced clinical care. Daktari is initially developing three diagnostic products based on the CarePlatform: a high-sensitivity cardiac troponin (hs-cTnl) cardiac distress screening test, a hepatitis C virus core antigen (HCV-cAg) confirmatory test being developed in collaboration with Merck, and an HIV viral load monitoring test. The Merck Global Health Innovation Fund, a venture capital arm of Merck, is an investor in Daktari. For more information, visit www.daktaridx.com.
0 Comments

Your comment will be posted after it is approved.


Leave a Reply.

    Archives

    November 2019
    October 2019
    August 2019
    July 2019
    June 2019
    May 2019
    April 2019
    March 2019
    February 2019
    January 2019
    December 2018
    November 2018
    October 2018
    September 2018
    August 2018
    July 2018
    June 2018
    May 2018
    April 2018
    March 2018
    February 2018
    January 2018
    December 2017
    November 2017
    October 2017
    September 2017
    August 2017
    July 2017
    June 2017
    May 2017
    April 2017
    March 2017
    February 2017
    January 2017
    December 2016
    November 2016
    October 2016
    September 2016
    August 2016
    July 2016
    June 2016
    May 2016
    April 2016
    March 2016
    February 2016
    January 2016
    December 2015
    November 2015
    October 2015
    September 2015
    August 2015
    July 2015
    June 2015
    May 2015
    April 2015
    March 2015
    February 2015
    January 2015
    December 2014
    November 2014
    October 2014
    September 2014
    August 2014
    July 2014
    June 2014
    May 2014
    April 2014
    March 2014
    February 2014
    January 2014
    December 2013
    November 2013
    October 2013
    September 2013
    August 2013
    July 2013
    June 2013
    May 2013
    April 2013
    March 2013
    February 2013
    January 2013
    December 2012
    November 2012
    October 2012
    September 2012
    August 2012
    July 2012
    June 2012
    May 2012
    April 2012
    March 2012
    February 2012
    January 2012
    December 2011
    November 2011
    October 2011
    September 2011
    August 2011
    July 2011
    June 2011
    May 2011

    Categories

    All

    RSS Feed

Privacy Policy